FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NYSE:XGNExagen Stock Price, Forecast & News

$13.22
+0.47 (+3.69 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.95
Now: $13.22
$13.45
50-Day Range
$11.00
MA: $12.56
$13.88
52-Week Range
$10.29
Now: $13.22
$29.86
Volume930 shs
Average Volume52,478 shs
Market Capitalization$167.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Exagen Inc. operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia. The company also offers Avise SLE Prognostic, a blood test that complements Avise SLE+CT; Avise MTX, a therapeutic drug monitoring test to measure levels of methotrexate polyglutamates; and Avise HCQ, a blood test for physicians to monitor blood levels of HCQ. In addition, it is developing Anti-TNF, a blood test to monitor the levels of anti-TNF bioactivity in patients with RA; Avise SLE Monitoring, a multi-analyte panel blood test for physicians to track the disease status of their SLE patients; and Avise RA, a blood test to determine bone damage or joint erosion. The company primarily serves rheumatologists in the United States. It was formerly known as Exagen Diagnostics, Inc. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone760-560-1501

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees142
Market Cap$167.06 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive XGN News and Ratings via Email

Sign-up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter.

Exagen (NYSE:XGN) Frequently Asked Questions

How has Exagen's stock been impacted by COVID-19 (Coronavirus)?

Exagen's stock was trading at $19.56 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XGN shares have decreased by 32.4% and is now trading at $13.22. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Exagen?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Exagen.

When is Exagen's next earnings date?

Exagen is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Exagen.

How were Exagen's earnings last quarter?

Exagen Inc. (NYSE:XGN) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.05. The firm earned $9.58 million during the quarter, compared to the consensus estimate of $7.68 million. View Exagen's earnings history.

What price target have analysts set for XGN?

3 analysts have issued 1-year price targets for Exagen's shares. Their forecasts range from $17.00 to $20.00. On average, they anticipate Exagen's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 39.9% from the stock's current price. View analysts' price targets for Exagen.

Has Exagen been receiving favorable news coverage?

News articles about XGN stock have trended negative on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Exagen earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Exagen.

Who are some of Exagen's key competitors?

What other stocks do shareholders of Exagen own?

Who are Exagen's key executives?

Exagen's management team includes the following people:
  • Mr. Fortunato Ron Rocca, Chief Exec. Officer, Pres and Director (Age 58)
  • Ms. Wendy Swedick CPA, Chief Financial Officer (Age 54)
  • Dr. Thierry Dervieux Pharm.d., Ph.d., Chief Scientific Officer, Medical Director of New York and Medical Laboratory Director (Age 51)
  • Ms. Waneta Coester Tuttle, Founder (Age 72)
  • Mr. Cole Harris, Co-Founder

When did Exagen IPO?

(XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO.

What is Exagen's stock symbol?

Exagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "XGN."

How do I buy shares of Exagen?

Shares of XGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Exagen's stock price today?

One share of XGN stock can currently be purchased for approximately $13.22.

How big of a company is Exagen?

Exagen has a market capitalization of $167.06 million. Exagen employs 142 workers across the globe.

What is Exagen's official website?

The official website for Exagen is avisetest.com.

How can I contact Exagen?

The company can be reached via phone at 760-560-1501.

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.